1. Home
  2. GPCR vs PCRX Comparison

GPCR vs PCRX Comparison

Compare GPCR & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GPCR
  • PCRX
  • Stock Information
  • Founded
  • GPCR 2016
  • PCRX 2006
  • Country
  • GPCR United States
  • PCRX United States
  • Employees
  • GPCR N/A
  • PCRX N/A
  • Industry
  • GPCR
  • PCRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • GPCR
  • PCRX Health Care
  • Exchange
  • GPCR Nasdaq
  • PCRX Nasdaq
  • Market Cap
  • GPCR 1.2B
  • PCRX 1.2B
  • IPO Year
  • GPCR 2023
  • PCRX 2011
  • Fundamental
  • Price
  • GPCR $27.28
  • PCRX $24.84
  • Analyst Decision
  • GPCR Strong Buy
  • PCRX Buy
  • Analyst Count
  • GPCR 8
  • PCRX 5
  • Target Price
  • GPCR $69.57
  • PCRX $32.40
  • AVG Volume (30 Days)
  • GPCR 1.0M
  • PCRX 548.0K
  • Earning Date
  • GPCR 11-12-2025
  • PCRX 11-05-2025
  • Dividend Yield
  • GPCR N/A
  • PCRX N/A
  • EPS Growth
  • GPCR N/A
  • PCRX N/A
  • EPS
  • GPCR N/A
  • PCRX N/A
  • Revenue
  • GPCR N/A
  • PCRX $705,848,000.00
  • Revenue This Year
  • GPCR N/A
  • PCRX $7.36
  • Revenue Next Year
  • GPCR N/A
  • PCRX $10.07
  • P/E Ratio
  • GPCR N/A
  • PCRX N/A
  • Revenue Growth
  • GPCR N/A
  • PCRX 2.25
  • 52 Week Low
  • GPCR $13.22
  • PCRX $15.16
  • 52 Week High
  • GPCR $43.46
  • PCRX $27.64
  • Technical
  • Relative Strength Index (RSI)
  • GPCR 68.40
  • PCRX 40.60
  • Support Level
  • GPCR $25.65
  • PCRX $24.31
  • Resistance Level
  • GPCR $28.12
  • PCRX $26.05
  • Average True Range (ATR)
  • GPCR 1.60
  • PCRX 0.74
  • MACD
  • GPCR 0.28
  • PCRX -0.26
  • Stochastic Oscillator
  • GPCR 89.60
  • PCRX 19.13

About GPCR Structure Therapeutics Inc.

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: